$2.04
Cellectis is a biotechnology business based in the US. Cellectis shares (CLLS) are listed on the NASDAQ and all prices are listed in US Dollars. Cellectis employs 216 staff and has a trailing 12-month revenue of around $12.1 million.
Our top picks for where to buy Cellectis stock
How to buy Cellectis stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – CLLS. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Cellectis stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Cellectis stock price (NASDAQ: CLLS)
Use our graph to track the performance of CLLS stocks over time.Cellectis shares at a glance
Latest market close | $2.04 |
---|---|
52-week range | $0.96 - $3.77 |
50-day moving average | $2.61 |
200-day moving average | $2.52 |
Wall St. target price | $7.00 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-1.37 |
Is it a good time to buy Cellectis stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Cellectis price performance over time
Historical closes compared with the close of $2.04 from 2024-07-05
1 week (2024-06-28) | |
---|---|
1 month (2024-06-07) | |
3 months (2024-04-05) | |
6 months (2024-01-05) |
1 year (2023-07-07) | |
---|---|
2 years (2022-07-07) | |
3 years (2021-07-07) | 14.34 |
5 years (2019-07-05) | 16.18 |
Cellectis financials
Revenue TTM | $12.1 million |
---|---|
Gross profit TTM | $24 million |
Return on assets TTM | -19.55% |
Return on equity TTM | -78.99% |
Profit margin | 0% |
Book value | $1.26 |
Market Capitalization | $187.2 million |
TTM: trailing 12 months
Cellectis share dividends
We're not expecting Cellectis to pay a dividend over the next 12 months.
Cellectis share price volatility
Over the last 12 months, Cellectis's shares have ranged in value from as little as $0.9628 up to $3.7735. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cellectis's is 3.091. This would suggest that Cellectis's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Cellectis overview
Cellectis S. A. , a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-715 and ALLO-605 for the treatment of multiple myeloma; ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics, Inc.
Frequently asked questions
What percentage of Cellectis is owned by insiders or institutions?Currently 9.379% of Cellectis shares are held by insiders and 14.667% by institutions. How many people work for Cellectis?
Latest data suggests 216 work at Cellectis. When does the fiscal year end for Cellectis?
Cellectis's fiscal year ends in December. Where is Cellectis based?
Cellectis's address is: 8, rue de la Croix Jarry, Paris, France, 75013 What is Cellectis's ISIN number?
Cellectis's international securities identification number is: US15117K1034 What is Cellectis's CUSIP number?
Cellectis's Committee on Uniform Securities Identification Procedures number is: 15117K103
More guides on Finder
-
6 best bitcoin ETFs to easily invest in bitcoin through your broker
We analyzed a number of bitcoin ETFs to determine which are best to invest in.
-
11 best trading platforms for beginners [July 2024]
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
-
6 best ETF brokers for low-cost fund investing [July 2024]
Check out our picks of the best ETF brokers for beginners, options trading, micro-investing and more.
-
5 best international stock brokers to invest in foreign assets
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
-
9 best discount brokers for low-cost trading and investing [July 2024]
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
-
9 best robo-advisors for affordable, automated portfolio management
Check out our picks of the best robo-advisors for new and experienced investors alike.
-
12 best stock apps of July 2024 to elevate your mobile trading
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
-
11 Robinhood alternatives you need to consider
Consider these Robinhood alternatives if you want advanced trading tools, more investment options or a different investing experience.
-
Webull vs. Robinhood
Compare pros, cons, research tools and reviews for these two trading platforms.
-
How to invest $50K for growth, passive income and diversification
There are many ways to invest and grow $50K depending on your financial situation, personal needs and goals.
Ask a Question